Search research articles
Contact Us
Filters
Showing results (11-20 of 72) with videos related to
Page
of 8
Sort By:
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 5, 2024
The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide
Daniel Umbricht, Martien J H Kas, Gerard R Dawson
Biological Psychiatry
|
March 21, 2002
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
Daniel Umbricht, Rene Koller, Franz X Vollenweider, et al.
Chimia
|
August 31, 2018
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient
Emmanuel Pinard, Edilio Borroni, Annette Koerner, et al.
Schizophrenia Research
|
September 30, 2014
Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome
Andor E Simon, Daniel Umbricht, Undine E Lang, et al.
Schizophrenia Bulletin
|
September 19, 2012
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia
Daniel C Javitt, Stephen R Zukin, Uriel Heresco-Levy, et al.
European Child & Adolescent Psychiatry
|
September 12, 2006
Developing services for the early detection of psychosis: a critical consideration of the current state of the art
Andor E Simon, Binia Roth, Solange Zmilacher, et al.
Frontiers in Psychiatry
|
November 16, 2020
Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients With Negative Symptoms
Daniel Umbricht, Wei-Yi Cheng, Florian Lipsmeier, et al.
Schizophrenia Bulletin
|
January 26, 2018
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
David Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Neuropharmacology
|
September 21, 2012
Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target
Celia Goeldner, Theresa M Ballard, Frederic Knoflach, et al.
The International Journal of Neuropsychopharmacology
|
April 4, 2001
Effects of risperidone on auditory event-related potentials in schizophrenia
Daniel Umbricht, Daniel Javitt, Gerald Novak, et al.
Page
of 8
Search research articles
Search
Showing results (11-20 of 72) with videos related to
Sort By:
Page
of 8
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology
|
September 5, 2024
The role of biomarkers in clinical development of drugs for neuropsychiatric disorders - A pragmatic guide
Daniel Umbricht, Martien J H Kas, Gerard R Dawson
Biological Psychiatry
|
March 21, 2002
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers
Daniel Umbricht, Rene Koller, Franz X Vollenweider, et al.
Chimia
|
August 31, 2018
Glycine Transporter Type I (GlyT1) Inhibitor, Bitopertin: A Journey from Lab to Patient
Emmanuel Pinard, Edilio Borroni, Annette Koerner, et al.
Schizophrenia Research
|
September 30, 2014
Declining transition rates to psychosis: the role of diagnostic spectra and symptom overlaps in individuals with attenuated psychosis syndrome
Andor E Simon, Daniel Umbricht, Undine E Lang, et al.
Schizophrenia Bulletin
|
September 19, 2012
Has an angel shown the way? Etiological and therapeutic implications of the PCP/NMDA model of schizophrenia
Daniel C Javitt, Stephen R Zukin, Uriel Heresco-Levy, et al.
European Child & Adolescent Psychiatry
|
September 12, 2006
Developing services for the early detection of psychosis: a critical consideration of the current state of the art
Andor E Simon, Binia Roth, Solange Zmilacher, et al.
Frontiers in Psychiatry
|
November 16, 2020
Deep Learning-Based Human Activity Recognition for Continuous Activity and Gesture Monitoring for Schizophrenia Patients With Negative Symptoms
Daniel Umbricht, Wei-Yi Cheng, Florian Lipsmeier, et al.
Schizophrenia Bulletin
|
January 26, 2018
Predictors of Placebo Response in Pharmacological Clinical Trials of Negative Symptoms in Schizophrenia: A Meta-regression Analysis
David Fraguas, Covadonga M Díaz-Caneja, Laura Pina-Camacho, et al.
Neuropharmacology
|
September 21, 2012
Cognitive impairment in major depression and the mGlu2 receptor as a therapeutic target
Celia Goeldner, Theresa M Ballard, Frederic Knoflach, et al.
The International Journal of Neuropsychopharmacology
|
April 4, 2001
Effects of risperidone on auditory event-related potentials in schizophrenia
Daniel Umbricht, Daniel Javitt, Gerald Novak, et al.
Page
of 8